Clinical evaluation of subcutaneous administration of cefepime - 04/05/20
Évaluation de l’administration du céfépime par voie sous-cutanée
, A. Mizrahi b, d, ⁎, G. Petitjean c, A. Le Monnier b, d, N. El Helali cBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 3 |
| Iconographies | 1 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
• | The subcutaneous route of administration for antibiotic therapy is convenient in outpatient settings or in geriatrics, but available data on cefepime is limited. |
• | Subcutaneous administration of cefepime resulted in a plasma concentration profile similar to intravenous cefepime administration. |
• | No local or systemic adverse effect attributable to the subcutaneous administration of cefepime were reported. |
Abstract |
Objectives |
Cefepime is a fourth-generation cephalosporin active against Pseudomonas aeruginosa and most Enterobacteriaceae. Intravenous (IV) administration is the standard route of prescription. However, subcutaneous administration (SC) may represent an interesting alternative. We aimed to evaluate SC administration of cefepime versus the IV route in geriatric patients.
Patients and methods |
Multicenter retrospective analysis in patients treated with cefepime by SC route who underwent plasma concentration monitoring.
Results |
Twelve patients were included in the SC group and matched to 12 patients in the IV group. The median and mean Cmin levels were 29.05mg/L [14.2–48.2]; 33.4mg/L (±21.8) in the SC group and 31.9mg/L [26.5–51.7]; 39.6mg/L (±27) (P=NS) in the IV group. No local SC administration-related complications were reported. No relapse was observed over six months of follow up.
Conclusion |
Subcutaneous use of cefepime seems to have the same clinical and microbiological effectiveness as parenteral administration.
Le texte complet de cet article est disponible en PDF.Keywords : Cefepime, Drug monitoring, Subcutaneous injection
Plan
| ☆ | Congress: RICAI 2018 – Paris – December 17th and 18th, 2018 – P352. |
Vol 50 - N° 3
P. 308-310 - mai 2020 Retour au numéro
Article précédent
- Stenotrophomonas maltophilia susceptibility to ceftazidime-avibactam combination versus ceftazidime alone
- C. Moriceau, M. Eveillard, C. Lemarié, R. Chenouard, H. Pailhoriès, M. Kempf
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?